Experimental drug plus radiation aims to tackle returning head and neck cancers
NCT ID NCT07156227
First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 5 times
Summary
This early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused radiation. The main goals are to find the safest dose and to see if the combination shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camonsertib (a drug that may stop tumor cell growth) combined with stereotactic body radiation therapy (precise radiation to tumors)
- What this could lead to
- If it works, this could point toward a new treatment option for patients with head and neck cancer that has returned or cannot be surgically removed.
- What could go wrong
- This is a very early Phase I trial with only 39 participants, so it is primarily testing safety and dosing. The combination may not effectively control the cancer or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A gentler path after surgery for HPV throat cancer?
- Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
- Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
- Aiming to spare the neck: could smarter radiation cut side effects in oral cancer?
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- Sharper radiation boost aims to tackle head and neck cancers that return